Abstract
A 69-year-old female patient underwent a choledochojejunostomy for unresectable duodenal papilla cancer with para-aortic lymph node metastases. Both tegafur-uracil(UFT) and cyclophosphamide were given orally every day after surgery. Twenty-eight months from the initiation of the chemotherapy the tumor had remarkably reduced and the objective response was evaluated as a PR. The patient is now doing well. Lymph node metastasis is considered an important prognostic factor of papilla Vater carcinoma, and especially with para-aortic lymph node metastases the long-term prognosis is poor. Combination chemotherapy using UFT and cyclophosphamide would be a therapeutic option for elderly or high-risk patients.
MeSH terms
-
Adenoma / drug therapy*
-
Adenoma / pathology
-
Administration, Oral
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / blood
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use*
-
Duodenal Neoplasms / blood
-
Duodenal Neoplasms / diagnostic imaging
-
Duodenal Neoplasms / drug therapy*
-
Duodenal Neoplasms / pathology
-
Duodenoscopy
-
Female
-
Humans
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use*
-
Time Factors
-
Tomography, X-Ray Computed
-
Uracil / administration & dosage
-
Uracil / therapeutic use*
Substances
-
Biomarkers, Tumor
-
Tegafur
-
Uracil
-
Cyclophosphamide